首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2020年 4期“自身免疫性肝炎” => 其他肝病 =>非诺贝特对非酒精性脂..
非诺贝特对非酒精性脂肪性肝病小鼠模型肠道菌群多样性的影响
Effect of fenofibrate on the diversity of intestinal flora in a mouse model of nonalcoholic fatty liver disease
文章发布日期:2020年03月11日  来源:  作者:张丹,周波,邓溢,等  点击次数:275次  下载次数:47次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的 探讨非诺贝特对非酒精性脂肪性肝病(NAFLD)小鼠肠道菌群多样性的影响。方法 将30只小鼠随机分为3组,正常组(n=10)、高脂组(n=10)、非诺贝特治疗组(n=10),高脂组与非诺贝特治疗组给予高脂饮食干预14周,正常组给予普通饮食14周。在满10周开始对非诺贝特治疗组给予非诺贝特灌胃治疗并继续给予高脂饮食4周,全程监测小鼠体质量变化;14周后收集3组粪便用于高通量测序16S rRNA分析菌群的多样性及差异;并收集肝组织进行HE染色及油红O染色观察脂肪变性情况。多组间比较采用单因素方差分析,进一步两两比较采用 LSD-t检验。结果 干预10周后,非诺贝特治疗组较高脂组体质量明显减轻(P<0.05)。HE染色及油红O染色显示非诺贝特治疗组脂肪沉积较高脂组明显减少。非诺贝特治疗组与高脂组肠道菌群存在明显差异,而与正常组肠道菌群具有相似性,非诺贝特治疗组拟杆菌门、疣微菌门、Faecalibaculum、Muribaculaceae_norank、阿克曼菌属丰度明显升高,厚壁菌门、放线菌门、梭菌属、Turicibacter、双歧杆菌属丰度降低。结论 拟杆菌门、疣微菌门丰度明显升高,厚壁菌门、放线菌门丰度降低在非诺贝特治疗NAFLD中可能存在积极意义。
【Abstract】:Objective To investigate the effect of fenofibrate on the diversity of intestinal flora in mice with nonalcoholic fatty liver disease (NAFLD). Methods A total of 30 mice were randomly divided into normal group, high-fat group, and fenofibrate treatment group, with 10 mice in each group. The mice in the high-fat group and the fenofibrate treatment group were given high-fat diet intervention for 14 weeks, and those in the normal group were given normal diet for 14 weeks. After 10 weeks of dietary intervention, the mice in the fenofibrate treatment group were given fenofibrate by gavage and high-fat diet for another 4 weeks, and the change in body weight was monitored during the whole process. Fecal samples were collected after 14 weeks, and high-throughput sequencing 16S rRNA was used to investigate the diversity and difference of intestinal flora. Liver tissue samples were collected, and HE staining and oil red O staining were performed to observe the degree of steatosis. A one-way analysis of variance was used for comparison between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results After 10 weeks of intervention, the fenofibrate treatment group had a significantly lower body weight than the high-fat group (P<0.05). The results of HE staining and oil red O staining showed that the fenofibrate treatment group had a significantly lower degree of fat deposition than the high-fat group. There was a significant difference in intestinal flora between the fenofibrate treatment group and the high-fat group, while there was no significant difference in intestinal flora between the fenofibrate treatment group and the normal group. The fenofibrate treatment group had significant increases in the abundance of Bacteroidetes, Verrucomicrobia, Faecalibaculum, Muribaculaceae_norank, and Akkermansia and significant reductions in the abundance of Firmicutes, Actinobacteria, Clostridium, Turicibacter, and Bifidobacterium. Conclusion The increases in the abundance of Bacteroidetes and Verrucomicrobia and the reductions in the abundance of Firmicutes and Actinobacteria suggest that fenofibrate may have positive significance in the treatment of NAFLD.
【关键字】:非酒精性脂肪性肝病; 非诺贝特; 肠道菌群; 小鼠,近交C57BL
【Key words】:nonalcoholic fatty liver disease; fenofibrate; intestinal flora; mice,inbred C57BL
【引证本文】:ZHANG D, ZHOU B, DENG Y, et al. Effect of fenofibrate on the diversity of intestinal flora in a mouse model of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(4): 829-834. (in Chinese)
张丹, 周波, 邓溢, 等. 非诺贝特对非酒精性脂肪性肝病小鼠模型肠道菌群多样性的影响[J]. 临床肝胆病杂志, 2020, 36(4): 829-834.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号